8 articles
Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, in a deal valued near $20 billion. The unit, which generated $9.3 billion in sales last
Johnson & Johnson agreed to a $5.5 billion settlement resolving nearly 70,000 lawsuits alleging its talc products caused ovarian cancer. The company denies the claims and switched to cornstarch-based
Johnson & Johnson beat Q2 sales and profit estimates, driven by strong growth in key drugs like Tremfya and Darzalex. It raised its full-year forecast despite challenges in its medical technology unit
Johnson & Johnson agreed to acquire Firefly Bio for $1 billion to bolster its oncology pipeline with Firefly's Firelink platform. The technology targets KRAS-driven cancers, offering potential treatme
A Los Angeles jury ruled in favor of Johnson & Johnson in a lawsuit claiming its talc products caused ovarian cancer. J&J faces over 67,000 similar suits but halted U.S. talc-based baby powder sales i
Johnson & Johnson will market four prescription drugs on the Trump administration's TrumpRx platform under an agreement to reduce prices and secure tariff exemptions. Specific medications remain undis
Johnson & Johnson beat first-quarter earnings estimates with $24.1 billion revenue, raising its full-year forecast despite a 60% drop in Stelara sales due to biosimilar competition. Growth in cancer a
EpiBiologics secured $107 million Series B funding backed by Google and Johnson & Johnson to advance protein-degrading drug candidates into human trials based on UCSF research.
ChemBrief